Keyword: Vertex Pharmaceuticals
Meyers retires as Gilead's commercial head, Kewalramani was promoted to Vertex's CMO, Recipharm CFO Stenqvist jumped ship to Sobi.
Reshma Kewalramani, M.D., has been promoted to CMO and EVP of global medicines development and medical affairs at Vertex.
CRISPR is a promising treatment for blood disorders, but it comes with challenges, such as off-target effects.
Vertex Pharma now has a pair of studies backing up its new drug VX-150, suggesting it can provide opioidlike pain relief without the addiction risks.
BTI will spend the cash on phase 2 trials of a once-failed cancer asset and an old drug repurposed for use in Alzheimer’s and schizophrenia.
VX-659 and VX-445 landed spots in experimental triple combinations designed to treat 90% of cystic fibrosis patients.
Vertex and CRISPR will co-develop a beta-thalassemia and sickle cell treatment, the first to come out of their $105 million partnership.
Moderna looks to take an AstraZeneca-partnered med into phase 2 and start on I-O, while making changes to its venture model.
R&D chief Narsimhan will replace retiring Jimenez as Novartis CEO, Stada names its fourth CEO in less than two years, Vertex poaches CFO from Ironwood.
The French drugmaker handed over another slice of the €290 million in milestones tied to the drug after getting a look at phase 1 data.